Wedbush raised the firm’s price target on Protagonist Therapeutics (PTGX) to $70 from $58 and keeps an Outperform rating on the shares.Optimize ...

Truist raised the firm’s price target on Protagonist Therapeutics (PTGX) to $76 from $60 and keeps a Buy rating on the shares. The firm cites ...

The joint development project of Protagonist Therapeutics and Johnson & Johnson (NYSE:JNJ) produced Icotrokinra as their ...

Results from the phase 3 ICONIC-LEAD study presented at this year’s American Academy of Dermatology (AAD) annual meeting ...

The market slump continued yesterday as President Donald Trump's "period of transition" fuels stagflation fears. It led to ...

We recently compiled a list of the 10 Firms Buck Market Bloodbath on Monday. In this article, we are going to take a look at ...

HC Wainwright reissued their buy rating on shares of Protagonist Therapeutics (NASDAQ:PTGX – Free Report) in a research note ...

Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Get Free Report) has been assigned an average recommendation of “Buy” from the nine research firms that are presently covering the stock, Ratings reports.

Protagonist Therapeutics stock broke out Monday after the company's Johnson & Johnson-partnered drug topped its rival from ...

Under the terms of the agreement, Redfin shareholders will receive 0.7926 shares of Rocket Class A common stock for each Redfin share—a 63% premium over Redfin’s 30-day volume-weighted average price.

On Monday, Protagonist Therapeutics, Inc. PTGX announced topline results from ANTHEM-UC Phase 2b study of icotrokinra ...

Protagonist Therapeutics shares were up 28% to $49.25 after the company reported positive topline results from a Phase 2b study of icotrokinra, conducted by partner Johnson & Johnson.